Aptevo Therapeutics (NASDAQ:APVO) Upgraded by StockNews.com to “Sell” Rating

StockNews.com upgraded shares of Aptevo Therapeutics (NASDAQ:APVOFree Report) to a sell rating in a report issued on Saturday.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $2.64 on Friday. The stock has a 50 day moving average price of $3.80 and a 200-day moving average price of $166.20. Aptevo Therapeutics has a 52-week low of $2.35 and a 52-week high of $207.33.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

Featured Stories

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.